Potential new targets for drug development in severe asthma
Open Access
- 1 January 2018
- journal article
- review article
- Published by Elsevier BV in World Allergy Organization Journal
- Vol. 11 (1), 30
- https://doi.org/10.1186/s40413-018-0208-1
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- T Cell–Derived IL-17 Mediates Epithelial Changes in the Airway and Drives Pulmonary NeutrophiliaThe Journal of Immunology, 2013
- High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effectsJournal of Allergy and Clinical Immunology, 2013
- Update on Anticytokine Treatment for AsthmaBioMed Research International, 2013
- Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled TrialsPLOS ONE, 2013
- IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contractionNature Medicine, 2012
- A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthmaClinical & Experimental Allergy, 2011
- Thymic Stromal Lymphopoietin Gene Promoter Polymorphisms Are Associated with Susceptibility to Bronchial AsthmaAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- A Novel, Orally Active CXCR1/2 Receptor Antagonist, Sch527123, Inhibits Neutrophil Recruitment, Mucus Production, and Goblet Cell Hyperplasia in Animal Models of Pulmonary InflammationThe Journal of pharmacology and experimental therapeutics, 2007
- Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cellsThe Journal of Experimental Medicine, 2007
- Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLPNature Immunology, 2002